Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules today announced that, to date, it has received patent grants from the European Patent Office (No. EP3048103B), the United State Patent and Trademark Office (No. US10280158B2) and Japan Patent Office (No. JP6470757B2), and the Australian Patent Office (No. AU2014323822B2) for CBP-307. These issuances broadly expand Connect Biopharma's intellectual property estate for CBP-307 beyond the patent issued by the China National Intellectual Property Administration (No. CN103450171B) in July 2015. The patents cover the composition of matter of the drug candidate and related compounds and have patent terms extending to no earlier than September 2033 for the patent issued in China and to September 2034 for the other patents.